View of Ribociclib plus letrozole in patients with hormone receptor‐positive, HER2‐negative advanced breast cancer with no prior endocrine therapy: subgroup analysis from the phase 3b CompLEEment‐1 trial

Return to Article Details Ribociclib plus letrozole in patients with hormone receptor‐positive, HER2‐negative advanced breast cancer with no prior endocrine therapy: subgroup analysis from the phase 3b CompLEEment‐1 trial Download Download PDF